FarmaKology Newsletter - Issue #35

Feb 25, 2020

Today's Startup

Healx

Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Our AI drug discovery platform leverages public and proprietary biomedical data and features the world’s leading knowledge graph for rare diseases. Combining this technology with patient insights and drug discovery expertise, our mission is to advance 100 rare disease treatments towards the clinic by 2025.

News

Atrin Pharmaceuticals, Predictive Technology Collaborate to Refine Clinical Trial Recruitment

Biopharma company Atrin Pharmaceuticals, a drug discovery and development company focused on molecules targeting DNA damage and repair pathways to treat cancer, and gene-based analytics company Predictive Technology Group say they have successfully tested a collaborative genomics analysis for more accurate clinical trial screening for ATRN-119, an ATR inhibitor with therapeutic potential across a broad range of cancers. The company anticipates initiating first-in-human trials this year.

Harvard, Guangzhou Institute to Collaborate on $115M Coronavirus Research Project

Researchers at Harvard University and the Guangzhou Institute of Respiratory Health in China will partner to develop therapies designed to prevent new Coronavirus infections and treat existing ones, through a $115 million research collaboration funded by Chinese real estate giant China Evergrande Group.

Point Biopharma Launches With Radiopharmaceutical Development Focus

POINT Biopharma, a newly formed pharmaceutical company, is combining a seasoned management team with strategic partnerships in radio-isotope supply, manufacturing technology and novel direct to patient targeting to revolutionize radiopharmaceutical drug development and commercialization.

FDA Grants IND Approval to Promising Anti-Cancer Agent Veyonda®

Noxopharm announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug application for Veyonda® for combination treatment with doxorubicin in patients with soft tissue sarcomas.